Navigation Links
Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
Date:1/8/2014

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects with high frequency episodic migraine, who experience headaches eight to 14 days per month. 

"Clinical data from six previous clinical studies of LBR-101, as well as emerging evidence of the potential role of anti-CGRP antibodies in the treatment of migraine, supports the expansion of our clinical program to include prevention of high frequency episodic migraine in addition to chronic migraine," said Steven P. James, president and CEO of Labrys Biologics. "Based on results from a recently completed Phase 1 study assessing the subcutaneous delivery of LBR-101, we will be investigating the once-monthly subcutaneous delivery of LBR-101 in both Phase 2 studies, which if successful, should make the product considerably more attractive in medical practice and to patients."

Both studies are multicenter, randomized, double-blind, placebo-controlled, parallel group, multi-dose studies. Approximately 225 and 270 patients are expected to complete the chronic migraine and high frequency episodic migraine studies, respectively.  Subjects will be randomized to receive placebo, a low dose or a high dose treatment once per month for three months. Primary efficacy endpoint for the chronic migraine trial captures the mean change from baseline in the number of hours with headache on the final month of the study (after 12 weeks of treatment). For the high frequency episodic migraine study, the primary endpoint measures the
'/>"/>

SOURCE Labrys Biologics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orthobiologics Market (Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others) is Expected to Reach USD 5,519.9 Million Globally in 2019: Transparency Market Research
2. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
3. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
4. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
5. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
6. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
7. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
8. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
9. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
10. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
11. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... is a detailed type of imaging that customs a ... called a mammogram, is used to support in the ... An x-ray (radiograph) is a noninvasive medical test that ...
(Date:5/27/2015)... senior marketing associate with the animal health division of Eli Lilly and ... setting in Bangkok, Thailand , will be among the ... respect and dignity is the guiding star for me and my fellow ... LillyPad blog . Donatelli and Lilly colleagues from ... , France , Ukraine ...
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9ffv95/2015_strategies ... "2015 Strategies in the European Coagulation Testing Market" ... comprehensive five-country report contains 500 pages, 120 tables, ... potential market entrants identify and evaluate business opportunities ... the next five years. The report ...
Breaking Medicine Technology:Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3European Coagulation Testing Market Strategies 2015 2
... of Having a Venous ThromboEmbolism (VTE) is Reduced ... Treated With,Clexane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20, ... PREVAIL (Prevention,of VTE after Acute Ischemic Stroke with ... The Lancet. The results of the trial showed,that ...
... Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused ... publication,of a research paper on two of ... paper appeared in the April issue,of the ... official Journal of the American Society of,Microbiology, ...
Cached Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
(Date:5/27/2015)... 27, 2015 The BBB Code of ... practices that enhance customer trust and confidence in business. ... Trust, eight principles that summarize important elements of creating ... standards for business accreditation by BBB. Businesses based in ... and complete application procedures will be accredited by BBB. ...
(Date:5/27/2015)... 2015 With the launch of the ... Network Management Module (NMM) tool, monitoring provider-network adequacy will ... of Atlantic Information Services, Inc.’s (AIS) Medicare Advantage News ... as well as analysis from industry experts on why ... coming to the NMM were announced at CMS’s recently ...
(Date:5/27/2015)... 27, 2015 The new http://www.carsonenergy.com ... Why investors should consider oil and gas investing, the ... wells are drilled, industry news, IRA investing, definitions and ... years of knowledge and experience is now in one ... to be able to access 24 hours a day, ...
(Date:5/27/2015)... Little Rock, AR (PRWEB) May 27, 2015 ... and Medix today announce a partnership to provide ... the Medix community. This collaboration seeks to strengthen ... skills measurement through CMSA’s CKP program. The mutually ... focused on identifying individual skills of talent in ...
(Date:5/27/2015)... View, CA (PRWEB) May 27, 2015 Coco ... Valley will be able to reach for Organic Coconut Water ... Coco Libre will be available at VIP areas, artist greenrooms, ... also be available at area hotels and on festival shuttle ... a partner this year,” said Noa Elan, Director of Strategic ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2
... Johns Hopkins School of Medicine have discovered that a natural ... as thunder god vine, or lei gong teng, and used ... arthritis works by blocking gene control machinery in the cell. ... issue of Nature Chemical Biology, suggests that the ...
... Unexpected results from a Scripps Research Institute and ModGene, ... to the liver instead of the brain as the source ... with this devastating condition. The findings could offer a relatively ... was published online today in The Journal of Neuroscience ...
... , THURSDAY, March 3 (HealthDay News) -- Staring into the ... have its benefits, but a downside to all that screen ... headaches. This cluster of symptoms is called "computer vision ... serious or even if it,s a new phenomenon. "Computer ...
... the vast literature on cancer to produce a next-generation ... cancer cells. These hallmarks of the disease provide ... will influence biomedical researchers in their quest for new ... Douglas Hanahan of cole Polytechnique Fdrale in Switzerland and ...
... School of Medicine have found that lactate, a type of ... the formation of long-term memory. These findings have important implications ... memory impairment and diabetes. The research is published in the ... The study is the first to closely evaluate the role ...
... By Steven Reinberg HealthDay Reporter , ... are 80 percent more likely to die prematurely than ... diabetes that,s killing them. Besides dying from vascular ... disease are also more likely to die prematurely from ...
Cached Medicine News:Health News:Solving a traditional Chinese medicine mystery 2Health News:Solving a traditional Chinese medicine mystery 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 2Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 4Health News:Computer Vision Syndrome: Fact or Fiction? 2Health News:Computer Vision Syndrome: Fact or Fiction? 3Health News:In search of cancer's common ground: A next-generation view 2Health News:Researchers find new mechanism behind the formation and maintenance of long-term memories 2Health News:Diabetes Ups Death Risk Overall, Study Shows 2
Headlight module is mounted on UltraLite Plus headband or sweatband....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: